Latest Breaking News On - Haijun dong - Page 1 : comparemela.com
BioDuro-Sundia Strengthens Leadership with New CFO and Operations SVP
mobilitytechzone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mobilitytechzone.com Daily Mail and Mail on Sunday newspapers.
BioDuro-Sundia Strengthens Leadership with New CFO and Operations SVP – Consumer Electronics Net
consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.
BioDuro-Sundia Completes First GMP Drug Product Manufacturing at New China Site – Consumer Electronics Net
consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.
Haijun Dong to Lead Next Phase of Growth for CRDMO
SAN DIEGO & SHANGHAI–(BUSINESS WIRE)–BioDuro-Sundia, a leading drug discovery and development services organization backed by Advent International, announced today the appointment of Haijun Dong, PhD, MBA as Chief Executive Officer.
Dong will take over from Cyrus K. Mirsaidi, who most recently led the company through its 2020 integration, establishing BioDuro-Sundia as the No. 3 CRDMO in the industry, with more than 2,000 employees and operations in 7 cities across China and the US. The executive team, now led by Dong, will continue to be co-located in both China and the US, providing balance for the global business units that support all aspects of drug discovery, development, and manufacturing both drug substance and drug product.
PharmaBlock Enters Strategic Partnership with Ascentage Pharma
News provided by
Share this article
Share this article
NANJING, China, Dec. 11, 2020 /PRNewswire/ PharmaBlock Sciences (Nanjing), Inc. (300725.SZ), a leading innovative chemistry product and service provider throughout the pharmaceutical R&D process, announced the signing of a strategic partnership agreement with Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases. The partnership aims to strengthen the strategic cooperation between the two companies in drug development and manufacturing.
As a long-term CDMO partner of Ascentage Pharma, PharmaBlock has witnessed many of its development projects advancing quickly from discovery to preclinical and clinical manufacturing. Under the terms of the agreement, PharmaBlock becomes the preferred CDMO partner of Ascentage Pharma, and the two